Prolonged use of antacids harms kidneys: Doctors

MUMBAI: Recent global studies suggesting that the prolonged use of widely prescribed anti-acidity pills to treat “gas” and heartburn might be linked to long-term kidney damage, acute renal disease and chronic kidney disease have sparked fresh debate in the medical community here.

Though a few initial reports about the association of these drugs — also called PPIs (proton pump inhibitors) — with kidney disease have been published in reputed international medical journals over the last couple of years, it is only now that there are studies suggesting that it’s more serious and linked to both acute kidney injury and chronic kidney disease, doctors told TOI.

Also, since these reports are mostly restricted to nephrology journals and limited to only specialists, many physicians may not be really aware of these adverse effects. Increasing concerns about these drugs could be the reason their safety profile was discussed at the Annual Conference of Nephrologists and at an Association of Physicians of India conference.

PPIs rank among the top-10 prescribed classes of drugs and are commonly used to treat acid reflux, indigestion, and peptic ulcers. They are prescribed across specialities, from orthopaedics and cardiology to internal medicine and surgery. A US-based nephrologist, Dr Pradeep Arora, spoke about the drug’s risks at the annual conference of the Indian Society of Nephrology in Delhi recently. He told TOI: “PPIs should be ideally prescribed in the approved indications, if possible for less than eight weeks. Beyond this, if a patient is on PPIs, kidney function and magnesium levels need monitoring.”

Most patients do not know about side-effects like CKD (chronic kidney disease) as in the early stages CKD from any cause usually shows no symptom., said Vijay Kher, chairman, nephrology, at Delhi-based Fortis Escorts. Though no advisory has been issued against the medicine, Dr Kher said drug regulatory authorities will be informed.

  • Related Posts

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per ml. The…

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    New Delhi: Serious legal gaps in the Drugs and Cosmetics Act, 1940, combined with acute shortages of manpower and infrastructure, continue to impede the Central Drugs Standard Control Organisation (CDSCO)…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development